[1] 梁聪,李维丽,陈春林,等. 基于中国大陆部分医院宫颈癌诊疗大数据的嗜神经浸润与临床病理参数相关性分析[J]. 中国实用妇科与产科杂志,2018,34(1):72-77. [2] Yao J, Zhou G, Wang Y, et al. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein–Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma[J]. Chin J Cancer,2017,36(1):34-36. [3] 王振国,李争,陈瑜. 宫颈癌组织中 KGF、KGFR 及 MMP-9的表达变化[J]. 山东医药,2016,56(1):50-52. [4] 罗安琪,韩瑞,吴芳,等. 不同分子亚型乳腺癌骨转移患者的临床特征和预后分析[J]. 西安交通大学学报(医学版),2017,38(5):740-743. [5] 张丽滢,李力. 分子进化理论在卵巢癌发生及多药耐药的研究进展[J]. 中国肿瘤生物治疗杂志,2017,24(5):553-557. [6] Takekuma M, Shimokawa M, Nishio S, et al. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis[J]. Cancer Sci,2018,32(7):56-58. [7] 钱莉莉,徐菲,宋伟国,等.局部晚期子宫颈癌新辅助化疗疗效分析[J].癌症进展,2017,15(5):501-504. [8] Abbasian Ardakani A, Reiazi R, Mohammadi A. A clinical decision support system using ultrasound textures and radiologic features to distinguish metastasis from tumor-free cervical lymph nodes in patients with papillary thyroid carcinoma[J]. J Ultrasound Med,2018,26(5):345-347. [9] Nanthamongkolkul K, Hanprasertpong J. Predictive factors of pelvic lymph node metastasis in early-stage cervical cancer[J]. Oncol Res Treat,2017,41(4):194-198. [10] Samouelian V, Mechtouf N, Leblanc E, et al. Sensitive molecular detection of small nodal metastasis in uterine cervical cancer using HPV16-E6/CK19/MUC1 cancer biomarkers[J]. Oncotarget,2018,9(31):34-36. [11] 张珊,官海涟,丁锦红,等. 宫颈癌及其癌前病变的分子标志物临床应用进展[J]. 实用妇产科杂志,2016,32(7):503-506. [12] 叶庆华,邵凌云,童晓文. 上皮间质转化的分子机制及在妇科肿瘤转移中的研究进展[J]. 中国妇产科临床杂志,2015,16(5):471-473. [13] 郑爱文,陈雅卿,方静,等. 早期子宫颈癌术后肺转移的临床病理特征及危险因素分析[J]. 中华妇产科杂志,2015,50(3):204-209. [14] 吴乾凤,高国兰,孔为民. Ⅰ～ⅡA2期宫颈癌淋巴结转移高危因素及对预后的影响[J]. 中国妇产科临床杂志,2016,17(5):407-409. [15] 王永良,陈美才. 惠州龙门地区妇女宫颈病变中p16INK4a蛋白与KGFR的表达及意义[J]. 检验医学与临床,2015,12(6):825-826.
2019, Vol. 26 
